4-Hydroxyaminopropiophenone (4-HAP) is a potent and selective inhibitor of monoamine oxidase A (MAO-A), an enzyme that breaks down neurotransmitters like serotonin, norepinephrine, and dopamine in the brain. It is synthesized through a multi-step process that involves the reaction of propiophenone with hydroxylamine. 4-HAP has been shown to exhibit antidepressant-like effects in animal models, potentially by increasing serotonin levels in the brain. However, its use as a therapeutic agent is limited due to its toxicity and potential for adverse effects. It is an important research tool for studying the role of MAO-A in various neurological and psychiatric disorders, including depression, anxiety, and Parkinson's disease.'
| ID Source | ID |
|---|---|
| PubMed CID | 65520 |
| SCHEMBL ID | 12826176 |
| MeSH ID | M0144732 |
| Synonym |
|---|
| p-hydroxyaminopropiophenone |
| para-hydroxylaminopropiophenone |
| propiophenone, 4'-hydroxylamino- |
| 1-propanone, 1-(4-(hydroxyamino)phenyl)- |
| 4-hydroxyaminopropiophenone |
| brn 2360943 |
| 55-34-5 |
| p-hydroxylaminopropiophenone |
| 4-hydroxylaminopropiophenone |
| propiophenone, 4'-(hydroxyamino)- |
| SCHEMBL12826176 |
| n-hydroxy-p-aminopropiophenon |
| DTXSID20203531 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral dosing of rats with the cyanide antidote 4-aminopropiophenone (PAPP), brought about peak methaemoglobin levels at 15-40 min, but peak levels were attained at at 15-25 min after intravenous dosing." | ( The formation of methaemoglobin by 4-aminopropiophenone (PAPP) and 4-(N-hydroxy) aminopropiophenone. Bright, JE; Inns, RH; Marrs, TC; Wood, SG, 1991) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||